1. Home
  2. SCNI vs ARTL Comparison

SCNI vs ARTL Comparison

Compare SCNI & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCNI
  • ARTL
  • Stock Information
  • Founded
  • SCNI 2003
  • ARTL 2011
  • Country
  • SCNI Israel
  • ARTL United States
  • Employees
  • SCNI N/A
  • ARTL N/A
  • Industry
  • SCNI Biotechnology: Biological Products (No Diagnostic Substances)
  • ARTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCNI Health Care
  • ARTL Health Care
  • Exchange
  • SCNI Nasdaq
  • ARTL Nasdaq
  • Market Cap
  • SCNI 3.2M
  • ARTL 3.1M
  • IPO Year
  • SCNI N/A
  • ARTL N/A
  • Fundamental
  • Price
  • SCNI $2.47
  • ARTL $6.86
  • Analyst Decision
  • SCNI
  • ARTL Buy
  • Analyst Count
  • SCNI 0
  • ARTL 2
  • Target Price
  • SCNI N/A
  • ARTL $30.00
  • AVG Volume (30 Days)
  • SCNI 1.1M
  • ARTL 14.8K
  • Earning Date
  • SCNI 08-14-2025
  • ARTL 08-12-2025
  • Dividend Yield
  • SCNI N/A
  • ARTL N/A
  • EPS Growth
  • SCNI N/A
  • ARTL N/A
  • EPS
  • SCNI N/A
  • ARTL N/A
  • Revenue
  • SCNI $658,000.00
  • ARTL N/A
  • Revenue This Year
  • SCNI N/A
  • ARTL N/A
  • Revenue Next Year
  • SCNI N/A
  • ARTL N/A
  • P/E Ratio
  • SCNI N/A
  • ARTL N/A
  • Revenue Growth
  • SCNI N/A
  • ARTL N/A
  • 52 Week Low
  • SCNI $1.90
  • ARTL $4.92
  • 52 Week High
  • SCNI $8.92
  • ARTL $9.30
  • Technical
  • Relative Strength Index (RSI)
  • SCNI 49.52
  • ARTL 59.07
  • Support Level
  • SCNI $2.15
  • ARTL $5.76
  • Resistance Level
  • SCNI $2.70
  • ARTL $6.15
  • Average True Range (ATR)
  • SCNI 0.22
  • ARTL 0.46
  • MACD
  • SCNI 0.01
  • ARTL -0.04
  • Stochastic Oscillator
  • SCNI 32.99
  • ARTL 69.53

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: